Tanaka J, Inuyama Y, Fujii M, Takaoka T, Hosoda H, Saito S
Auris Nasus Larynx. 1985;12 Suppl 2:S261-6. doi: 10.1016/s0385-8146(85)80070-5.
A new anticancer agent, UFT which is a mixture of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil in a molar ratio of 1:4 was administered orally at a dose of 600 mg/day every day. Forty-three patients were evaluable. Eight patients achieved a complete response and eight achieved a partial response with an overall response rate of 37.2%. In terms of response by histology, a response rate was 32.4% (11/34) in cases of squamous cell carcinoma and 75% (3/4) in cases of adenocarcinoma. A response rate by primary site was 57.1% in the nose and paranasal sinuses, 50.0% in the oropharynx and 30.0% in the oral cavity. A response rate was 36.1% in patients with prior treatment and 42.9% in patients with no prior treatment, but there was no statistical significance. Eight of 43 patients developed toxic effects. Most of them were mild such as anorexia, nausea, and stomatitis, but in one case of maxillary sinus carcinoma, severe bone marrow suppression was observed. UFT is a considerably effective and useful drug in the treatment of head and neck cancer. It is possible to increase cure rate by examining various usages of UFT.
一种新型抗癌药物优福定（UFT），它是1-(2-四氢呋喃基)-5-氟尿嘧啶与尿嘧啶按1:4摩尔比混合而成的，每天口服剂量为600毫克。43例患者可进行评估。8例患者达到完全缓解，8例达到部分缓解，总缓解率为37.2%。就组织学反应而言，鳞状细胞癌病例的缓解率为32.4%（11/34），腺癌病例的缓解率为75%（3/4）。按原发部位的缓解率，鼻和鼻窦为57.1%，口咽为50.0%，口腔为30.0%。既往接受过治疗的患者缓解率为36.1%，未接受过治疗的患者缓解率为42.9%，但无统计学意义。43例患者中有8例出现毒性反应。大多数为轻度，如厌食、恶心和口腔炎，但在上颌窦癌的1例患者中观察到严重的骨髓抑制。优福定在头颈部癌的治疗中是一种相当有效且有用的药物。通过研究优福定的各种用法有可能提高治愈率。
